The agreement, known as an Agreed iPSP, acts as a prerequisite for a future Biologics License Application. By aligning with the FDA, Armata establishes a structured development framework for addressing complicated Staphylococcus aureus bacteremia, a condition currently lacking sufficient treatment options for vulnerable pediatric groups, including newborns and premature infants. Dr. Deborah Birx, CEO of Armata, stated the plan reflects a commitment to both adult and pediatric patient populations.
In section Releases
Armata Pharmaceuticals Secures FDA Path for Pediatric Bacteremia Study
Armata Pharmaceuticals has reached an agreement with the U.S. Food and Drug Administration on an initial pediatric study plan for its experimental drug AP-SA02. This regulatory milestone clears the way for the company to evaluate its bacteriophage therapy in patients under 17 following the completion of adult clinical trials.
Under the Pediatric Research Equity Act, the FDA determined that since the disease's pathophysiology remains consistent across age groups, pediatric investigations should proceed only after the company secures safety and efficacy data from its adult Phase 3 program. Armata expects to launch that pivotal study in the second half of 2026. Once the adult data is collected, the company will conduct a single, multicenter, open-label trial to assess clinical outcomes in children, prioritizing safety while expanding the scope of its pathogen-specific bacteriophage technology.
Comments (0)
No comments yet. Be the first!